Physician profile
David H Johnson
NPI 1124312376
$189,775.67
in general payments reported to CMS, 2019-2025
23 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,246 · 2020: $9,069 · 2021: $37.28 · 2022: $17K · 2023: $27K · 2024: $44K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Consulting Fee: $43K · Travel and Lodging: $25K · Food and Beverage: $8,018 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,609.39 |
| Consulting Fee | $43,473.51 |
| Travel and Lodging | $24,922.76 |
| Food and Beverage | $8,018.05 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $88,085.15 | 2019-2025 | |
| Exact Sciences Corporation | $78,957.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $17,452.32 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,521.78 | 2022-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $875.68 | 2022-2025 | |
| Celgene Corporation | $759.24 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $701.89 | 2022-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $317.82 | 2019-2023 | Resolution 360 Clip |
| Lilly USA, LLC | $241.56 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.57 | 2023-2024 | Xifaxan, Plenvu, Trulance |
| Regeneron Healthcare Solutions, INC. | $134.53 | 2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $125.00 | 2024 | |
| Genzyme Corporation | $123.73 | 2022-2023 | |
| Braintree Laboratories, INC. | $89.02 | 2019-2023 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $51.30 | 2020-2024 | Dificid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $37.15 | 2019-2020 | |
| Ucb, INC. | $20.81 | 2019 | |
| Amgen INC. | $19.01 | 2022 | |
| Aimmune Therapeutics, INC. | $18.82 | 2024 | |
| Fresenius Kabi USA, LLC | $17.69 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $15.44 | 2023 | Rebyota |
| Ardelyx, INC. | $14.57 | 2024 | Ibsrela |
| Erbe USA INC | $12.73 | 2023 | Erbe |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.